A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment

Clinical trial NCT07413042 · RECRUITING

Trial details

NCT number: NCT07413042
Sponsor: Peking University Cancer Hospital & Institute
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

SCLC, Extensive Stage

Start date: 2026-01-20
Primary completion: 2026-12-31
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.